BioAffinity stockholders approve reverse stock split, 2024 plan share increase to 1M

bioAffinity Technologies, Inc.

Stockholders approved reverse stock split at ratio of 1-for-2 to 1-for-250, at board's discretion.
Plan amended to increase shares reserved under 2024 Plan from 66,666 to 1,000,000.
Approved warrant exercise of up to 271,500 shares and anti-dilution adjustments (floor $4.50 for warrants, $3.00 for Series B).
Six directors elected: Maria Zannes, Steven Girgenti, Peter Knight, Jamie Platt, Roberto Rios, John J. Oppenheimer.
Ratified WithumSmith+Brown as independent auditor for fiscal year 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.